Differences in Lipid Measurements by Antiretroviral Regimen Exposure in Cohorts from Asia and Australia by Achhra, Amit C. et al.
Hindawi Publishing Corporation
AIDS Research and Treatment
Volume 2012, Article ID 246280, 9 pages
doi:10.1155/2012/246280
Clinical Study
Differencesin Lipid Measurements by Antiretroviral Regimen
Exposure inCohorts from Asia and Australia
Amit C.Achhra,1 Janaki Amin,1 Jennifer Hoy,2 Junko Tanuma,3 Thira Sirisanthana,4
DavidNolan,5 TutiMerati,6 andMichelleGiles2
1TheKirbyInstituteforInfectionandImmunityinSociety(FormerlytheNationalCentreinHIVEpidemiologyandClinicalResearch),
Faculty of Medicine, University of New South Wales, Sydney, NSW 2052, Australia
2Infectious Diseases Unit, Alfred Hospital and Monash University, Melbourne, VIC 3004, Australia
3AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo 162-8655, Japan
4Research Institute for Health Sciences, Chiang Mai University, Chiang Mai 50200, Thailand
5Centre for Clinical Immunology and Biomedical Statistics, Murdoch University and Royal Perth Hospital, Perth, Australia
6Faculty of Medicine, Udayana University and Sanglah Hospital, Bali 80233, Indonesia
Correspondence should be addressed to Amit C. Achhra, aachhra@kirby.unsw.edu.au
Received 24 October 2011; Accepted 11 March 2012
Academic Editor: Ann Duerr
Copyright © 2012 Amit C. Achhra et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
We explored the mean diﬀerences in routinely measured lipids (total cholesterol, triglycerides, and high-density lipoprotein
cholesterol) according to exposure to diﬀerent combination antiretroviral regimens in Asian (n = 2051) and Australian
(predominantly Caucasian, n = 794) cohorts. The regimen was deﬁned as at least 3 antiretroviral drugs with at least 2 nucleoside-
reversetranscriptases(NRTIs)andeitherofatleastoneproteaseinhibitor(PI)ornon-nucleoside-reversetranscriptases(NNRTIs).
We categorised cART regimens as: NRTIs as tenofovir based or not; NNRTIs as nevirapine or efavirenz (but not both); and PI as
atazanavir based or not. We found that the impact of various antiretroviral regimens on lipids in Asian and Australian cohorts was
only diﬀerent by cohort for total cholesterol (P for interaction between regimen and cohort: <0.001) but not in case of other lipids
(P forinteraction:>0.05).Thediﬀerencesintotalcholesterolwerehoweversmallandunlikelytobeofclinicalsigniﬁcance.Overall,
tenofovir with nevirapine or atazanavir was associated with the most favorable lipids, while the PI regimens without tenofovir and
atazanavir were associated with least favorable lipids. We conclude that the impact of various ART regimens on lipids is largely
similar in Asian and Australian cohorts and that the newer drugs such as tenofovir and atazanavir are likely to provide similar
beneﬁt in terms of lipid proﬁles in both populations.
1.Introduction
Combination antiretroviral therapy (cART) for HIV infec-
tion is associated with adverse changes in lipid proﬁles and
can include elevation in total cholesterol and triglycerides,
which may increase the risk of coronary heart disease (CHD)
[1–4]. Moreover, diﬀerent classes of cART and drugs within
each class have diﬀerential impacts on lipids [2]. Protease-
inhibitors (PIs) are associated with more signiﬁcant changes
in lipid proﬁle than nucleoside and nonnucleoside reverse
transcriptase inhibitors (NRTIs and NNRTIs, resp.) [2, 3, 5].
And within NNRTI class, efavirenz (EFV) is associated with
greater changes in the lipid proﬁle than nevirapine (NVP)
[2, 5, 6]. Also tenofovir (TDF) and atazanavir (ATV) are
known to have a favorable impact on lipids [5, 7, 8].
Drugs such as TDF, EFV, and ATV are becoming increas-
ingly available in low-middle-income countries, including
Asia [9, 10]. However, much of our knowledge about the
relative impact of diﬀerent cART regimens on lipids comes
mainly from clinical trials and cohort studies from European
or North-American settings [2, 4, 7, 8]. The impact of cART
on lipids may vary in Asian settings due to diﬀerences in
race/ethnicity, dietary, environmental, and lifestyle factors
[11–13]. This has been demonstrated in other settings2 AIDS Research and Treatment
where the magnitude of change in total cholesterol and
t r i g l y c e r i d e sd u et oP I sd i ﬀered between African Americans
and Caucasians, highlighting the possible role of race
[11, 12]. These ﬁndings illustrate the need for verifying
our assumptions about the relative impact of diﬀerent
cART regimens on diverse populations, including Asian
populations.
Observational cohort studies can complement informa-
tion from clinical trials, and allow us to examine the eﬀects
of art medications in the context of combination regimens,
as opposed to head-to-head comparisons of selected drugs
in clinical trials. In the present study, we aim to compare
the relative impact of various cart regimens on lipid pro-
ﬁles in Asian and Australian cohorts using data from the
treat Asia and the Australian HIV observational databases
(TAHOD and AHOD, resp.), which are formed on similar
methodology and are known to be predominantly Asian and
Caucasian, respectively [14].
2. Methods
2.1. The TAHOD and AHOD Cohorts. TAHOD and AHOD
are clinical cohort studies of HIV-infected patients in Asia
and Australia, respectively, and are part of the International
Epidemiologic Databases to evaluate AIDS initiative. Both
cohorts have similar methodologies, which have been previ-
ously published [15, 16]. Brieﬂy, prospective data collection
wascommencedin2003forTAHODandin1999forAHOD,
with retrospective data being provided where available. In
TAHOD, data are collected from 17 clinical sites in the Asian
region,whereasforAHOD,dataarecollectedfrom27clinical
sites throughout Australia. Written informed consent was
not a requirement of sites in TAHOD unless required by
the site’s local ethics committee because data are collected in
an anonymous form, while in AHOD consent was obtained
from all patients recruited at the time of enrolment. The
TAHODandAHODcohortsareknowntobepredominantly
of Asian and Caucasian ethnic composition, respectively
[14].
Ethical approval for both the cohorts was obtained from
the University of New South Wales, Sydney, Australia, and
all other relevant institutional review boards. Data for both
TAHOD and AHOD are transferred electronically to the
KirbyInstitutetwiceperyearandincludethesamesetofcore
variables. All data are subject to standardized quality control
procedures.
2.2. Outcome. The outcomes of interest were mean (i) total
cholesterol, (ii) triglycerides, (iii) high-density lipoprotein
cholesterol (HDL-C) measured in mmol/L, and (iv) total
cholesterol:HDL-C ratio. Lipid values are measured accord-
ing to the local sites’ standard of care in each cohort,
and when measured, are captured during routine data
transfer. TAHOD only records fasting lipids. In AHOD, both
fasting and nonfasting lipids along with the fasting status
are recorded. Further details of laboratory standards and
methods at each site were not available.
Data collection on lipid proﬁles started later in AHOD
(mediandate:January,2007),comparedtoTAHOD(median
date: March, 2006). The lipid values before starting cART
(i.e., while patients were ART naive) were not available in
most patients, and therefore changes from pre- to post-cART
were not analysed. Mean lipid measurements were compared
by diﬀerent regimens and cohort.
2.3. Deﬁnition and Classiﬁcation of Antiretroviral Regimens.
T h ec A R Tr e g i m e nv a r i a b l ew a sd e ﬁ n e da sar e g i m e n
containing at least 3 antiretroviral drugs, including at least
twoNRTIsandeitherofatleastonePIoranNNRTI.Inorder
to evaluate the net eﬀect of a combination regimen, rather
thanthatofasingledrugoraclass,wedeﬁnedeightmutually
exclusiveregimens.WecategorisedcARTregimensas:NRTIs
as TDF based (NRTIs + TDF) or not (NRTIs); NNRTIs as
NVPo rEFV(b u tnotboth);andP IasA TVbased(P I+A TV)
or not (PI).
Based on these categories, the following mutually exclu-
sive regimens were deﬁned: (i) NRTIs (+TDF) + NVP; (ii)
NRTIs (+TDF) + EFV; (iii) NRTIs + NVP; (iv) NRTIs +
EFV; (v) NRTIs (+TDF) + PIs (+ATV); (vi) NRTIs (+TDF)
+ PI; (vii) NRTIs + PI (+ATV); (viii) NRTIs + PI. In all
analyses, regimen (i) NRTIs (+TDF) + NVP was used as
the reference group, as this regimen was thought to have the
most favourable impact on lipids.
2.4. Inclusion Criteria and Time-Points Analysed. Patients
from TAHOD and AHOD were eligible for inclusion in
the analysis if they started cART and had at least one lipid
measurement within the ﬁrst 24 months of cART com-
mencement. Time at risk was deﬁned as time spent on any
of the regimens described previously and risk time started
from the commencement of that regimen. Follow-up was
censoredatﬁrstof24-monthexposuretoregimenofinterest,
date of death, loss to follow-up, or 31 March, 2010. Lipids
values measured at the 6-monthly intervals in the ﬁrst 24
months of start of cART were used. Thus each patient on
e a c hr e g i m e nc o u l dh a v eu pt o4m e a s u r e m e n t s( 1i ne a c h
interval). If more than one measurement was available in
a given interval, one measured earliest in the given interval
was used in the analysis. Intermittent changes in therapy
including stopping part or all of a regimen for less than
14 days were not considered a stop in time at risk for that
regimen. Each patient could contribute data to more than
one regimen.
2.5. Variables and Statistical Analysis. The following ap r i o r i
confounders were included in all models:
(1) ﬁxed variables: cohort (TAHOD/AHOD), gender,
HIV transmission group (homosexual contact ± in-
travenous drug user (IDU), IDU ± heterosexual,
heterosexual, and other), and hepatitis B and C
coinfection (deﬁned as HBV surface antigen and
HCV antibody positive, resp.);
(2) variables measured closest to the start of each cART
regimen within past 6 months to 1 month after theAIDS Research and Treatment 3
start of the regimen of interest: CD4+ T-cell count
(categorised as <200, 200–350, and >350 cells/μL);
H I VR N Av i r a ll o a d( c a t e g o r i s e da s<500, >500–
<10,000, and >10,000copies/mL); and body mass
index (BMI) (categorised as <18.5, 18.5–25, 25–30,
and >30kg/m2);
(3) variables recalculated at the start of each cART regi-
men: cumulative cART exposure and age.
We performed longitudinal data analysis using random
eﬀects models to take into account repeated lipid measures
(deﬁned previously). Since all lipid parameters were nor-
mally distributed with minimal skewness, data were not
transformed. Separate models were ﬁtted for each outcome.
All models included time on regimen with lipid data,
categorised as 6 monthly intervals. The interaction between
the regimen and the cohort variables was assessed for
each outcome. We also conducted the following sensitivity
analyses: (i) restricting AHOD data to only lipid values
which were documented to be taken as fasting in AHOD,
(ii) excluding patients with missing BMI data, (iii) including
only those with known Caucasian ethnicity in AHOD, and
(iv) additional adjustment for stavudine (d4t) use in the
multivariable model, as it was more common in TAHOD
than AHOD.
Data were analysed using STATA version 10 (STATA
Corporation, College Station, TX, USA).
3. Results
There were 2845 participants (2051 in TAHOD and 794
in AHOD) who met the inclusion criteria. In TAHOD,
736 (35.9%) were Chinese, 654 (31.9%) were Thai, 152
(7.4%) were Cambodian (Khmer), 100 (4.9%) were Japanese
and 62 (3%) were Indian. Table 1 describes the patient
characteristics at study entry for each cohort.
There were a total of 7897 total cholesterol values (5602
in TAHOD and 2295 in AHOD), 7293 triglyceride values
(5002 in TAHOD and 2291 in AHOD), and 4669 HDL-C
values (2949 in TAHOD and 1720 in AHOD). The frequency
of total cholesterol measurements by regimen and cohort
is shown in Table 2. The most common NRTI combina-
tionsforwhichtotalcholesterolmeasurementswereavailable
in TAHOD were zidovudine (AZT)/lamivudine (3TC) (39%
of all measurements) and d4t/3TC (30% of all measure-
ments) and in AHOD TDF/emtricitabine (FTC) (29% of
all measurements) and abacavir (ABC)/3TC (18% of all
measurements).Thedistributionwassimilarfortriglycerides
and HDL-C. In TAHOD and AHOD, 52% and 46% of
measurements were taken while on NNRTI-based regimens,
respectively. Of all the measurements on PI-based regimens,
greater than 95% were on ritonavir-boosted regimens.
Patients contributed data to the median of 1 regimen
(range: 1 to 4) with a median of 2 lipid measurements
(IQR: 1–4) per patient. All measures of CD4 cell count,
HIV viral load, and BMI were collected within 35 days of
commencing the diﬀerent ART regimens. Participants from
TAHOD were more likely to be younger and female and have
heterosexually acquired infection, hepatitis B coinfection,
detectable HIV VL, lower median CD4+ count, shorter time
spent on cART, lower BMI, lower mean total cholesterol,
and higher HDL-C than those from AHOD (Table 1). Also a
higher proportion of TAHOD participants had missing BMI
and HIV viral load values compared with those in AHOD
(Table 1).
3.1. Total Cholesterol. The relationship between mean
total cholesterol and cART regimen diﬀered by cohort
(TAHOD/AHOD) (P<0.001, test for interaction). Overall,
the mean total cholesterol was slightly lower for TAHOD
participants, compared to AHOD participants, after adjust-
ment for demographic and HIV-related characteristics, in
most of the regimens (Figure 1(a)). When compared to
the NRTIs (+TDF) + NVP regimen (reference group), the
NRTIs + PI regimen was associated with greater mean total
cholesterol in both cohorts, with a slightly greater diﬀerence
in AHOD participants (mean diﬀerence: +0.78mmol/L,
95% CI: 0.57 to 1.00) compared to TAHOD participants
(mean diﬀerence: +0.23mmol/L, 95% CI: 0.02 to 0.44);
NRTIs (+TDF) + PI (+ATV) regimen was associated with
greater mean total cholesterol in AHOD (mean diﬀerence:
−0.20mmol/L, 95% CI: −0.43 to 0.02) as compared to
TAHOD (mean diﬀerence: −0.62mmol/L, 95% CI: −1.23 to
−0.02).
3.2. Triglycerides, HDL-C, and Total Cholesterol: HDL-C
Ratio. There was no signiﬁcant interaction between cART
regimen and the cohort type (P>0.05, test for interac-
tion) for triglycerides, HDL-C, and total cholesterol: HDL-
Cr a t i o .Table 3 provides adjusted analyses for each of
these outcomes. As compared to the NRTIs (+TDF) +
NVP regimen (reference group), the NRTIs + PI regimen
was associated with the highest mean triglycerides (mean
diﬀerence: 1.13mmol/L, 95% CI: 0.83 to 1.43) and total
cholesterol:HDL-C ratio (mean diﬀerence: 0.75, 95% CI:
0.47 to 1.03), followed by the NRTIs (+TDF) + PI regimen
(mean diﬀerence in triglycerides: 1.06mmol/L, 95% CI: 0.73
to 1.38, and mean diﬀerence in total cholesterol:HDl-C
ratio: 0.66, 95% CI: 0.37 to 0.95), while NRTIs (+TDF) +
PI (+ATV) regimen was not associated with a signiﬁcant
diﬀerence in triglycerides (mean diﬀerence: 0.15mmol/L,
95% CI: −0.22 to 0.52) and total cholesterol:HDL-C ratio
(mean diﬀerence: 0.29, 95% CI: −0.04 to 0.62). Also, the
NRTIs + EFV regimen was associated with increase in
triglycerides (mean diﬀerence: 0.64mmol/L, 95% CI: 0.34 to
0.95) and total cholesterol:HDL-C ratio (mean diﬀerence:
0.29,95%CI0.01to0.56).TheTAHODcohort,ascompared
to AHOD, had higher mean triglycerides, but not total
cholesterol:HDL-C ratio. Figures 1(b) and 1(c) provide the
graphical representation of the adjusted mean triglycerides
and total cholesterol:HDL-C ratio for each regimen and
cohort, respectively.
When compared to the reference group, the NRTIs +
NVP regimen and the NRTIs+EFV regimen were associated
with higher mean HDL-C (mean diﬀerence of: 0.15mmol/L,
95% CI: 0.08 to 0.21 and 0.09mmol/L, 95% CI: 0.03 to 0.16,4 AIDS Research and Treatment
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Figure 1: Adjusted Mean Lipids by regimen and cohort. Interaction between impact of regimen and cohort variables on lipids: (a) mean
total cholesterol, (b) mean triglycerides, and (c) mean total cholesterol:HDL-C ratio. A statistically signiﬁcant interaction suggests impact
of regimen on lipids diﬀered in magnitude by the cohort. Triglycerides were higher for TAHOD as compared to AHOD irrespective of the
regimen, but the interaction between regimen and cohort was not signiﬁcant. Means were ap r i o r iadjusted for time on given regimen, HBV
and HCV confections, age, gender, HIV RNA viral load copies/mL, CD4+ T-cell count, BMI, cumulative exposure to cART at baseline, and
HIV exposure category. ∗Reference category. Horizontal line shows the value of constant (mean lipid value in reference category). Error bars
indicate95%conﬁdenceinterval.AHOD:AustralianHIVObservationalDatabase;ATV:Atazanavir;EFV:Efavirenz;NNRTIs:nonnucleoside
reversetranscriptaseinhibitors;NRTI:Nucleosidereversetranscriptaseinhibitors;NVP:Nevirapine;PI:proteaseinhibitor;TAHOD:TREAT
Asia HIV Observational Database; TDF: Tenofovir. Key. NRTIs are TDF based (NRTIs + TDF) or not (NRTIs) and PI as ATV based (PI +
ATV) or not (PI).
resp.). Other regimens were not signiﬁcantly diﬀerent to the
reference regimen.
3.3. Sensitivity Analyses. Forty-ﬁve percent of all of the
AHOD measurements were taken fasting. Ethnicity was
known in AHOD in 80% of participants, of whom greater
than 80% were Caucasian. All of the sensitivity analyses,
except for exclusion of missing BMI data, yielded very simi-
lar results, in terms of direction of eﬀect, magnitude, and
signiﬁcance, as those from full analyses (data not presented).
Since BMI was missing in a signiﬁcant proportion of
participants in both cohorts (Table 1), restriction of analysis
to only patients with known BMI provided results that were
of similar direction and magnitude of the eﬀect, however
in some cases less statistically signiﬁcant, because of loss of
power.AIDS Research and Treatment 5
Table 1: Patient characteristics at study entry.
Characteristics
AHOD,
n = 794
n (%)
TAHOD,
n = 2053
n (%)
P∗
Age (years)
Mean ± SD 45 (±9.8) 38.6( ±10) <0.001
Gender
Male 761 (96) 1,484 (72.2) <0.001
Female 30 (3.8) 567 (27.6)
Transgender∗∗∗ 03 (0.4) 02 (0.1)
HIV exposure category
Homosexual contact
± IDU 618 (78.4) 485 (23.7) <0.001
IDU ± heterosexual 25 (3.2) 45 (2.2)
Heterosexual 65 (8.2) 1,341 (65.6)
Other 80 (10.2) 174 (8.5)
Missing 06 (0.7) 08 (0.4)
HBV coinfection
Negative 649 (81.8) 1,376 (67) <0.001
Positive 22 (2.8) 171 (8.3)
Missing/never tested 123 (15.5) 506 (24.6)
HCV coinfection
Negative 631 (79.5) 1,365 (66.5) <0.001
Positive 87 (11) 128 (6.2)
Missing/never tested 76 (10) 560 (27.3)
HIV RNA <
500copies/mL 326 (41) 372 (18) <0.001
Missing 58 (7.3) 880 (43)
CD4+ count cells/μL 360 (219–569) 161 (50–280) <0.001∗∗
Median (IQR)
Missing 58 (7.3) 264 (12.9)
Cumulative exposure to
cART in years
Median (IQR) 2 (0–8.2) 0 (0–0.2) <0.001∗∗
Number ART naive 320 (40.3) 1460 (71)
Body mass index (kg/m2)
Mean (±SD) 24 (±3.4) 21 (±3.4) <0.001
Missing 528 (66.5) 1016 (49.5)
Total cholesterol mmol/L
Mean (±SD) 5.15 (±1.3) 4.88 (±1.4) <0.001
Triglycerides mmol/L
Mean (±SD) 2.44 (±2) 2.40 (±2.3) 0.678
HDL-C mmol/L
Mean (±SD) 1.15 (±0.5) 1.25 (±0.4) <0.001
∗Comparison by t-test for continuous variables and the χ2 test for
noncontinuous variables. ∗∗Comparison by Wilcoxon rank-sum test. A:
AHOD: Australian HIV Observational Database; T: TAHOD: TREAT
Asia HIV Observational Database. cART: combinational antiretroviral
therapy; HBV: hepatitis B coinfection; HCV: hepatitis C coinfection; IDU:
Intravenous drug user; IQR: interquartile range; SD: standard deviation.
∗∗∗Transgender participants were classiﬁed as males in the multivariable
analyses.
4. Discussion
In this study, we examined the mean diﬀerences in lipids
between various cART regimens in TAHOD and AHOD
cohorts. We found that the relationship between regimen
and lipids diﬀered by cohort only in the analysis of total
cholesterol level. For total cholesterol, the magnitude of
eﬀect of regimen diﬀered between cohorts such that TAHOD
participantstendedtohaveslightlylowertotalcholesterolfor
most regimens (most notably for the NRTIs (+TDF) + PI
(+ATV) and the NRTIs + PI regimens). Overall, we found
that the NRTIs (+TDF) + NVP and the NRTIs (+TDF) +
PI (+ATV) regimens were associated with the most favorable
lipid proﬁle, whereas the NRTIs + PI and the NRTIs +
EFV regimens were associated with the least favorable lipid
proﬁles.
These regimen/lipid association ﬁndings are consistent
with the literature from Western countries [5–8,17].The few
studiesthathavereportedlipidresultsfromAsianpopulation
also suggest an adverse impact of PI-based and EFV-based
regimens on lipids as compared to non-PI-based and NVP-
based regimens, respectively [18, 19]. However, these studies
were performed in clinical-trial populations, and in one
study [19], NVP was given at 400mg once a day, instead of
the recommended 200mg twice a day dosing schedule. Also,
they did not report usage of TDF- or ATV-based regimens.
The observed diﬀerences in mean total cholesterol
between TAHOD and AHOD cohorts, though statistically
signiﬁcant, were of small magnitude. The diﬀerences could
be due to variations in race/ethnicity or dietary, environ-
mental, and lifestyle factors [20]. The clinical relevance of
these diﬀerences, particularly the impact of these diﬀerences
on overall risk of CHD, is uncertain. In our study, TAHOD
participants had average total cholesterol up to 0.5mmol/L
lower than AHOD for the NRTIs + PI regimen (Figure 1(a)).
Studies on treated HIV-infected populations have suggested
that a diﬀerence of 1mmol/L in total cholesterol may be
associated with diﬀerence of about 25% in risk of CHD [21,
22]. Further, TAHOD participants, for any given regimen,
had higher triglycerides which have been associated with
greater risk of CHD [23]. The CHD events in cART-treated
HIV patients are thought to be multifactorial in origin,
with a possible role of dyslipidemia, cART, HIV-associated
inﬂammatoryprocess,andtraditionalriskfactors[1,21].We
did not have data on other CHD risk factors, with which we
could calculate the overall Framingham risk score for each
cohort. Future studies should therefore evaluate their impact
on risk of CHD events in treated HIV populations in Asia.
There are further limitations to this study. We divided
each class of ART according to those shown to have
favorable impact on lipids, that is, TDF, ATV, and NVP
[5, 7, 8]. However, such a classiﬁcation did not allow us
to examine the impact of other individual drugs in each
class. Further, we did not have information on use of
lipid-lowering medications, which are likely to diﬀer bet-
ween TAHOD and AHOD. It is likely that since TAHOD
participants were younger and mostly from low-middle in-
come countries, they may have a lower rate of use of lipid-
lowering medications, as compared to those in AHOD.6 AIDS Research and Treatment
Table 2: Number and frequency of total cholesterol measurements by type of regimen and cohort.
cART Regimen
AHOD
No. of
patients∗
AHOD median (range)
no. of measurements per
patient
AHOD no.
(%) of
measurements
TAHOD no.
of patients∗
TAHOD median (range)
no. of measurements per
patient
TAHOD no.
(%) of
measurements
NRTIs (+TDF) + NVP 122 2 (1–6) 247 (10.8) 70 1 (1–4) 108 (1.9)
NRTIs (+TDF) + EFV 131 2 (1–4) 245 (10.7) 90 1 (1–4) 147 (2.6)
NRTIs + NVP 155 2 (1–6) 342 (14.9) 696 1 (1–8) 1157 (20.6)
NRTIs + EFV 97 2 (1–4) 211 (9.2) 684 2 (1–10) 1487 (26.5)
NRTIs (+TDF) + PI
(+ATV) 140 1 (1–5) 266 (11.6) 20 1 (1–4) 28 (0.5)
NRTIs (+TDF) + PI 187 2 (1–7) 410 (17.9) 137 3 (1–6) 367 (6.5)
NRTIs + PI (+ATV) 78 2 (1–5) 178 (7.7) 232 3 (1–6) 610 (10.9)
NRTIs + PI 184 2 (1–6) 396 (17.2) 620 3 (1–12) 1698 (30.3)
Total 1094 2295 (100) 2548 5602 (100)
∗Each patient could contribute to more than one regimen. AHOD: Australian HIV Observational Database; ATV: Atazanavir; EFV: Efavirenz; NNRTI: non-
nucleoside reverse transcriptase inhibitors; NRTIs: nucleoside reverse transcriptase inhibitors; NVP: nevirapine; PI: protease inhibitor; TAHOD: TREAT Asia
HIV Observational Database; TDF: tenofovir. Key. NRTIs are TDF based (NRTIs + TDF) or not (NRTIs) and PI as ATV based (PI + ATV) or not (PI).
Table 3: Adjusted analyses for triglycerides, HDL-C, and total cholesterol:HDL-C ratio.∗∗
Covariate Mean diﬀerence in
triglycerides mmol/L (95% CI)
Mean diﬀerence in HDL-C
mmol/L (95% CI)
Mean diﬀerence in total
cholesterol:HDL-C ratio (95%
CI)
Regimen
NRTIs (+TDF) + NVP Reference Reference Reference
NRTIs (+TDF) + EFV 0.17 (−0.19 to 0.53) 0.01 (−0.06 to 0.08) 0.16 (−0.16 to 0.47)
NRTIs + NVP 0.58 (0.29 to 0.87) 0.15 (0.08 to 0.21) 0.13 (−0.12 to 0.39)
NRTIs + EFV 0.64 (0.34 to 0.95) 0.09 (0.03 to 0.16) 0.29 (0.01 to 0.56)
NRTIs (+TDF) +
PI(+ATV) 0.15 (−0.22 to 0.52) −0.03 (−0.11 to 0.05) 0.29 (−0.04 to 0.62)
NRTIs (+TDF) + PI 1.06 (0.73 to 1.38) −0.02 (−0.09 to 0.05) 0.66 (0.37 to 0.95)
NRTIs + PI(+ATV) 0.57 (0.24 to 0.90) 0.03 (−0.05 to 0.10) 0.34 (0.02 to 0.65)
NRTIs + PI 1.13 (0.83 to 1.43) 0.01 (−0.06 to 0.07) 0.75 (0.47 to 1.03)
P< 0.001 <0.001 <0.001
Cohort
AHOD Reference Reference Reference
TAHOD 0.33 (0.11 to 0.55) 0.04 (−0.01 to 0.09) −0.16 (−0.40 to 0.08)
P 0.003 0.146 0.187
Table shows independent eﬀects of regimen and cohort variables in adjusted analyses. Since the interaction term between these variables was not signiﬁcant,
it was not included in the models. Figure 1 shows the interaction between regimen and cohort variables.
∗∗Multivariablemodelswereaprioriadjustedfortimeongivenregimen,HepatitisBand/orCcoinfections,age,gender,HIVRNAviralloadcopies/mL,CD4+
T-cell count, BMI, cumulative exposure to cART at the start of regimen, and HIV exposure category. AHOD: Australian HIV Observational Database, ATV:
Atazanavir;cART:combinationalantiretroviraltherapy;CI:conﬁdenceinterval;EFV:Efavirenz;HBV:HepatitisBco-infection;HCV:HepatitisCco-infection;
IDU: Intravenous drug user; NNRTI: nonnucleoside reverse transcriptase inhibitors; NRTI: nucleoside reverse transcriptase inhibitors, NVP: nevirapine, PI:
protease inhibitor, TAHOD: TREAT Asia HIV Observational Database; TDF: Tenofovir. Key. NRTIs are TDF based (NRTIs + TDF) or not (NRTIs) and PI as
ATV based (PI + ATV) or not (PI).
However, TAHOD participants had lower total cholesterol
for most regimens than those in AHOD, suggesting residual
confounding, racial diﬀerences, or possibly higher use of
lipid lowering medications. Also, lipid values were measured
in site-speciﬁc laboratories which may introduce variation
in results. However, such a variation is unlikely to result
in any systematic diﬀerences in total cholesterol that we
observed.Furthermore,patientsinAHODtendedtobemore
treatment-experienced than TAHOD; however, adjusting
for cumulative cART exposure did not change our results.
Nevertheless, any residual confounding from these and other
unmeasured factors cannot be ruled out. Lastly, we did not
have pre-cART lipid data to compare with post-cART data in
eachcohort,whichwouldhaveprovidedclearercomparisons
of change in lipids in response to cART between the cohorts.
Keeping these limitations in mind, our results were however
robust when restricted to those (i) documented to be taken
after over-night fasting, (ii) with documented race/ethnicity,AIDS Research and Treatment 7
and (iii) adjusting for diﬀerential use of d4t, suggesting that
these factors were unlikely to impact our results.
StrengthsofourstudyincludeTAHODandAHODbeing
founded on similar methodology thereby reducing the like-
lihood of confounding due to methodological diﬀerences.
Also, the large sample size available allowed us to analyse
several regimens, including those with TDF and ATV, which
arelessfrequentlyusedinlow-middleincomecountries[10].
Moreover,availabilityoflipidmeasurementsonseveraltime-
pointsoneachregimenallowedustoadjustfortimespenton
each regimen of interest.
In summary, our ﬁndings suggest that the impact of
various ART regimens on lipids is largely similar in TAHOD
and AHOD cohorts and that the newer drugs such as TDF
and ATV are likely to provide similar beneﬁt in terms of lipid
proﬁles in both populations. We also found that TAHOD
participants may have slightly lower mean total cholesterol
for most regimens, although the clinical signiﬁcance of this
diﬀerence is uncertain. These ﬁndings contribute to the gap
in evidence from Asian settings. Future studies should report
pre- to post-ART monitoring of lipids and information on
Framingham risk score in diverse populations.
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